163 related articles for article (PubMed ID: 24998378)
1. Discovery of triazines as selective PDE4B versus PDE4D inhibitors.
Hagen TJ; Mo X; Burgin AB; Fox D; Zhang Z; Gurney ME
Bioorg Med Chem Lett; 2014 Aug; 24(16):4031-4. PubMed ID: 24998378
[TBL] [Abstract][Full Text] [Related]
2. Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.
Donnell AF; Dollings PJ; Butera JA; Dietrich AJ; Lipinski KK; Ghavami A; Hirst WD
Bioorg Med Chem Lett; 2010 Apr; 20(7):2163-7. PubMed ID: 20202838
[TBL] [Abstract][Full Text] [Related]
3. Discovery of selective PDE4B inhibitors.
Naganuma K; Omura A; Maekawara N; Saitoh M; Ohkawa N; Kubota T; Nagumo H; Kodama T; Takemura M; Ohtsuka Y; Nakamura J; Tsujita R; Kawasaki K; Yokoi H; Kawanishi M
Bioorg Med Chem Lett; 2009 Jun; 19(12):3174-6. PubMed ID: 19447034
[TBL] [Abstract][Full Text] [Related]
4. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the design of selective phosphodiesterase 4B inhibitors.
Fox D; Burgin AB; Gurney ME
Cell Signal; 2014 Mar; 26(3):657-63. PubMed ID: 24361374
[TBL] [Abstract][Full Text] [Related]
6. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Gangwal RP; Damre MV; Das NR; Dhoke GV; Bhadauriya A; Varikoti RA; Sharma SS; Sangamwar AT
J Mol Graph Model; 2015 Apr; 57():89-98. PubMed ID: 25687765
[TBL] [Abstract][Full Text] [Related]
7. Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
Zhou ZZ; Ge BC; Chen YF; Shi XD; Yang XM; Xu JP
Bioorg Med Chem; 2015 Nov; 23(22):7332-9. PubMed ID: 26526739
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of selective phosphodiesterase 4B inhibitors based on ginger phenolic compounds.
Xing M; Akowuah GA; Gautam V; Gaurav A
J Biomol Struct Dyn; 2017 Oct; 35(13):2910-2924. PubMed ID: 27608741
[TBL] [Abstract][Full Text] [Related]
9. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design.
Srivani P; Usharani D; Jemmis ED; Sastry GN
Curr Pharm Des; 2008; 14(36):3854-72. PubMed ID: 19128237
[TBL] [Abstract][Full Text] [Related]
10. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
[TBL] [Abstract][Full Text] [Related]
12. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
[TBL] [Abstract][Full Text] [Related]
13. Pyrazolopyridines as potent PDE4B inhibitors: 5-heterocycle SAR.
Mitchell CJ; Ballantine SP; Coe DM; Cook CM; Delves CJ; Dowle MD; Edlin CD; Hamblin JN; Holman S; Johnson MR; Jones PS; Keeling SE; Kranz M; Lindvall M; Lucas FS; Neu M; Solanke YE; Somers DO; Trivedi NA; Wiseman JO
Bioorg Med Chem Lett; 2010 Oct; 20(19):5803-6. PubMed ID: 20732811
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 4 inhibitors as airways smooth muscle relaxant agents: synthesis and biological activities of triazine derivatives.
Leroux F; van Keulen BJ; Daliers J; Pommery N; Hénichart JP
Bioorg Med Chem; 1999 Mar; 7(3):509-16. PubMed ID: 10220036
[TBL] [Abstract][Full Text] [Related]
15. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
16. Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
Skoumbourdis AP; Leclair CA; Stefan E; Turjanski AG; Maguire W; Titus SA; Huang R; Auld DS; Inglese J; Austin CP; Michnick SW; Xia M; Thomas CJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3686-92. PubMed ID: 19464886
[TBL] [Abstract][Full Text] [Related]
17. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
Wang H; Peng MS; Chen Y; Geng J; Robinson H; Houslay MD; Cai J; Ke H
Biochem J; 2007 Dec; 408(2):193-201. PubMed ID: 17727341
[TBL] [Abstract][Full Text] [Related]
18. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
19. Investigating the role of N-terminal domain in phosphodiesterase 4B-inhibition by molecular dynamics simulation.
Sharma V; Wakode S
J Biomol Struct Dyn; 2021 Aug; 39(12):4270-4278. PubMed ID: 32552529
[TBL] [Abstract][Full Text] [Related]
20. Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
Chłoń-Rzepa G; Jankowska A; Ślusarczyk M; Świerczek A; Pociecha K; Wyska E; Bucki A; Gawalska A; Kołaczkowski M; Pawłowski M
Eur J Med Chem; 2018 Feb; 146():381-394. PubMed ID: 29407965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
